Earnings Call Insights: Charles River Laboratories International, Inc. (CRL) Q4 2025 Management View James Foster, Chairman, President & CEO, stated that 2025 results landed at the upper end of the revenue and non-GAAP EPS guidance, highlighting improvements in DSA net bookings and a stabilized biopharma demand environment. Strategic initiatives were advanced, including acquisitions and a renewed ...
Earnings Call Insights: Charles River Laboratories International, Inc. (CRL) Q4 2025 Management View James Foster, Chairman, President & CEO, stated that 2025 results landed at the upper end of the revenue and non-GAAP EPS guidance, highlighting improvements in DSA net bookings and a stabilized biopharma demand environment. Strategic initiatives were advanced, including acquisitions and a renewed focus on scientific innovation, positioning Charles River as a leader in preclinical drug development. Foster reported, "We were pleased that our 2025 financial results were at the upper end of the revenue and non-GAAP earnings per share ranges that we provided in November." He also announced the acquisitions of K.F. (Cambodia) and PathoQuest, which are expected to enhance the company’s supply chain and testing capabilities. DSA net book-to-bill improved to 1.1x in the fourth quarter, with biotech clients driving a steady, sequential increase. Foster indicated cautious optimism for continued favorable demand trends into 2026. Foster shared, "We also continue to make progress on our plan to divest businesses totaling approximately 7% of 2025 annual revenue. These processes and negotiations with potential buyers are ongoing and we continue to expect the planned divestitures will be completed by middle of 2026." Foster announced his retirement effective in May and introduced Birgit Girshick as the incoming CEO. Birgit Girshick, Corporate Executive VP & COO, provided 2026 guidance and discussed the expectation for organic revenue to range from down 1% to at least flat, with operating margin improvement of 20 to 50 basis points. "This is expected to translate into non-GAAP earnings per share in a range from $10.70 to $11.20, representing growth of approximately 4% to 9%," Girshick stated. Girshick also announced that Glenn Coleman will join as CFO in April and Kerry Dailey as Chief Legal Officer in March. Michael Knell, Interim CFO, explained, "On a reported basis, we expect rev...
Energy startup Heron Power has raised a $140 million Series B to build a 40-gigawatt US manufacturing facility for its advanced electrical equipment. Heron’s CEO Drew Baglino discusses the demand coming from renewable power and AI data center projects. He joins Ed Ludlow on “Bloomberg Tech.” (Source: Bloomberg)
Energy startup Heron Power has raised a $140 million Series B to build a 40-gigawatt US manufacturing facility for its advanced electrical equipment. Heron’s CEO Drew Baglino discusses the demand coming from renewable power and AI data center projects. He joins Ed Ludlow on “Bloomberg Tech.” (Source: Bloomberg)
Investing.com -- Microsoft President Brad Smith cautioned that American tech companies should "worry a little bit" about subsidies Chinese competitors receive from their government in the artificial intelligence race.
Investing.com -- Microsoft President Brad Smith cautioned that American tech companies should "worry a little bit" about subsidies Chinese competitors receive from their government in the artificial intelligence race.
Dr. Jay Bhattacharya, director of the National Institutes of Health, during a tour of the Broad Institute on December 5, 2025. Jonathan Wiggs | Boston Globe | Getty Images U.S. National Institutes of Health Director Jay Bhattacharya will take over as acting director of the Centers for Disease Control and Prevention, a Trump administration official said on Wednesday. The New York Times first report...
Dr. Jay Bhattacharya, director of the National Institutes of Health, during a tour of the Broad Institute on December 5, 2025. Jonathan Wiggs | Boston Globe | Getty Images U.S. National Institutes of Health Director Jay Bhattacharya will take over as acting director of the Centers for Disease Control and Prevention, a Trump administration official said on Wednesday. The New York Times first reported the news on Wednesday. Health and Human Services Deputy Security Jim O'Neill is currently acting CDC director, having taken over in August after HHS Secretary Robert F. Kennedy Jr. fired the former director less than a month into her tenure. O'Neill will leave both his roles are part of a larger shakeup of health department leadership, and will be offered a different role in the administration not within HHS, the administration official told Reuters on Wednesday. His departure was first reported by Politico on Friday.
Wednesday's trading session is proving to be a thrilling one for ImmunityBio (NASDAQ: IBRX) shareholders. As of 1:50 p.m. ET today the biopharma stock is up an incredible 33.1%. The reason? Unsurprisingly, an approval of its breadwinning drug in another huge market. ImmunityBio's oncology drug Anktiva had already been approved as a treatment for certain forms of bladder cancer as early as 2024, fo...
Wednesday's trading session is proving to be a thrilling one for ImmunityBio (NASDAQ: IBRX) shareholders. As of 1:50 p.m. ET today the biopharma stock is up an incredible 33.1%. The reason? Unsurprisingly, an approval of its breadwinning drug in another huge market. ImmunityBio's oncology drug Anktiva had already been approved as a treatment for certain forms of bladder cancer as early as 2024, for the record, when the United States' FDA gave the immunotherapy the green light. The United Kingdom followed suit in the middle of 2025, with the Kingdom of Saudi Arabia coming around in January of this year. On Wednesday, however, the company announced that the European Union's regulatory commission has approved the combination of its Anktiva and vaccine Bacillus Calmette-Guérin (BCG) as treatment for non-muscle invasive bladder cancer in the 30 countries it represents. Continue reading
Anna Webber/Getty Images Entertainment A couple of Wall Street's most high-profile investors made sizable bets on emerging-market exchange-traded funds ahead of this year's rally, while some other hedge funds rebalanced crowded U.S. mega-cap holdings during the last quarter of 2025. Fresh 13F filings out earlier in the week showed that billionaire investor Stanley Druckenmiller's Duquesne Family O...
Anna Webber/Getty Images Entertainment A couple of Wall Street's most high-profile investors made sizable bets on emerging-market exchange-traded funds ahead of this year's rally, while some other hedge funds rebalanced crowded U.S. mega-cap holdings during the last quarter of 2025. Fresh 13F filings out earlier in the week showed that billionaire investor Stanley Druckenmiller's Duquesne Family Office purchased about 3.5M shares and call options in the iShares MSCI Brazil ETF ( EWZ ) in Q4 2025, before its 20% year-to-date climb amid a broader rotation away from U.S. growth and a weaker U.S. dollar ( DXY ). Still, it closed out its stake in the Global X MSCI Argentina ETF ( ARGT ). At the same time, David Tepper's Appaloosa Management bought a new, 1.88M-share position in the iShares MSCI South Korea ETF ( EWY ), which has surged some 35% since the start of Q1 2026. On the tech AI trade, Tiger Global trimmed its stakes in Microsoft ( MSFT ), Nvidia ( NVDA ) and Amazon ( AMZN ) during the three months ended Dec. 31, 2025. Saving Chase Coleman a headache, the so-called Magnificent Seven ( MAGS ) stocks are down YTD in part because of growing uncertainty about the pace of AI-driven earnings growth in the wake of a capex boom. But not every fund stepped back from AI/tech, with Bill Ackman's Pershing Square disclosing a nearly $2B bet on Meta Platforms ( META ). Coatue Management, the technology-focused investment firm led by founder and portfolio manager Philippe Laffont, also slightly pared its wagers on Meta ( META ) and Nvidia ( NVDA ), but significantly boosted stakes in Netflix ( NFLX ) and Amazon ( AMZN ). Similarly, Paul Tudor Jones's Tudor Investment fund liquidated its holding in Meta ( META ) and made new purchases in Alphabet C shares ( GOOG ), further supporting what appears to be a broader rebalancing within hedge funds' AI/tech exposure. U.S. equities drifted up in the October-December period, with the Dow Jones Industrial Average ( DJI ) +3.5%, S&P 500 I...
JannHuizenga/iStock Unreleased via Getty Images Bank of America ( BAC ) on Wednesday introduced a new loyalty program to increase client engagement. The no-fee program, called BofA Rewards, is available to any client with a BofA personal checking account, requires no minimum balance, and is " designed to reward and recognize clients for their full relationship across their Bank of America banking ...
JannHuizenga/iStock Unreleased via Getty Images Bank of America ( BAC ) on Wednesday introduced a new loyalty program to increase client engagement. The no-fee program, called BofA Rewards, is available to any client with a BofA personal checking account, requires no minimum balance, and is " designed to reward and recognize clients for their full relationship across their Bank of America banking and Merrill investing accounts," the company said. Starting on May 27, millions of clients will be eligible for the program that offers such benefits as credit cards, cash-back deals, banking services, and curated experiences. Based on clients' membership tier and program engagement, the BofA Rewards benefits can range from $150 to $4,000 in annual value per person. Bank of America ( BAC ) said more than 30M existing clients are currently eligible for the program. While there's no minimum balance to join the program, balance amounts do determine a client's membership tier — Member tier: less than $30K; Preferred Plus tier: $30K to less than $100K; Preferred Honors tier: $100K to less than $1M; and Premier tier: $1M and above. The program is meant to provide reward offerings to recognize clients' goals at every life stage, BofA said. Rewards include credit card reward bonuses of 10%-75% on everyday purchases with eligible credit cards, cash-back deals on more than 15K brands, exclusive discounts on home and auto loans, and enhanced fraud and identity monitoring. Preferred Honors and and Premier tier members can get reimbursed for popular subscriptions from streaming, entertainment, and news services, with credits of up to $96 per year for Preferred Honors and up to $180 per year for Premier tier members. Bank of America ( BAC ) stock rose 1.0% in Wednesday afternoon trading. More on Bank of America Bank Of America: It Doesn't Have To Be An Or/Or Story Bank of America Corporation (BAC) Presents at Bank of America Financial Services Conference 2026 Transcript Bank Of America P...
Mitch Marner scores in overtime to seal 4-3 win Canadians lose star Sidney Crosby to injury Nick Suzuki tied the game on a deflection with 3:27 left, Mitch Marner scored in overtime, and Canada avoided what would have been a stunning quarter-final exit at the Olympics by rallying to beat the Czech Republic 4-3 on Wednesday. Canada fell behind with 7:42 remaining when Ondrej Palat scored off a pass...
Mitch Marner scores in overtime to seal 4-3 win Canadians lose star Sidney Crosby to injury Nick Suzuki tied the game on a deflection with 3:27 left, Mitch Marner scored in overtime, and Canada avoided what would have been a stunning quarter-final exit at the Olympics by rallying to beat the Czech Republic 4-3 on Wednesday. Canada fell behind with 7:42 remaining when Ondrej Palat scored off a pass from Martin Necas. The goal sent the Czech bench and fans into a wild celebration, but their excitement was short-lived. Continue reading...
Cosmos (CRYPTO: ATOM) is among the leading decentralized blockchain projects focused on high-performance interoperability. Through its core Inter-Blockchain Communication (IBC) protocol, Cosmos aims to enable fast, secure transactions for millions of users seeking to benefit from applications spanning multiple blockchains. Unfortunately for investors in Cosmos and its native ATOM token, it's been ...
Cosmos (CRYPTO: ATOM) is among the leading decentralized blockchain projects focused on high-performance interoperability. Through its core Inter-Blockchain Communication (IBC) protocol, Cosmos aims to enable fast, secure transactions for millions of users seeking to benefit from applications spanning multiple blockchains. Unfortunately for investors in Cosmos and its native ATOM token, it's been a pretty consistent downward ride over the past year, with this token losing nearly 50% of its value over this time frame. Much of this move can be directly correlated to some rather unfriendly commentary from Christopher Goes (co-founder of Anoma), who believes the death certificate for Cosmos has been signed. His commentary centers on the idea that many major hubs have shifted to maintenance mode or collapsed on the Cosmos network, while other prominent projects have left the ecosystem altogether. Cosmos bulls will undoubtedly disagree with this thesis , and there is one key update this past week that appears to be spurring an uptick in investor demand for this large-cap cryptocurrency . Let's dive into why this token surged 7.6% today over the past 24 hours (as of 1:30 p.m. ET), and where it may be headed from here. Continue reading
March ICE NY cocoa (CCH26 ) today is down -139 (-4.11%), and March ICE London cocoa #7 (CAH26 ) is down -158 (-6.48%). Cocoa prices are falling sharply today, with NY cocoa posting a 2.5-year nearest-futures low and London cocoa plunging to a 2.75-year low. International cocoa buyers are reluctant...
March ICE NY cocoa (CCH26 ) today is down -139 (-4.11%), and March ICE London cocoa #7 (CAH26 ) is down -158 (-6.48%). Cocoa prices are falling sharply today, with NY cocoa posting a 2.5-year nearest-futures low and London cocoa plunging to a 2.75-year low. International cocoa buyers are reluctant...
nullplus/iStock via Getty Images The last few years have been a really difficult time for shareholders of Clarus Corporation ( CLAR ). The last article that I wrote about the company, in fact the only article that I wrote about it, was published in March of 2022. Back at that time, I said that it wasn't a bad play. But I wasn't terribly excited about it either. Even though I am generally drawn to ...
nullplus/iStock via Getty Images The last few years have been a really difficult time for shareholders of Clarus Corporation ( CLAR ). The last article that I wrote about the company, in fact the only article that I wrote about it, was published in March of 2022. Back at that time, I said that it wasn't a bad play. But I wasn't terribly excited about it either. Even though I am generally drawn to companies in the outdoor space, I believed that the stock was not cheap enough to justify a bullish outlook. Since then, revenue, profits, and cash flows have all taken a hit. This has caused the stock to drop 83.7% at a time when the S&P 500 is up 49.9%. Valuing the company is difficult at this stage. And that's simply because profits and most cash flow metrics are negative. We have seen a bit of a recovery when it comes to domestic operations. But on the whole, the company is clearly struggling. There is the hope that some asset sales might create value for shareholders. But with management even unwilling to project what the near-term outlook might be, I would say that it would be wise for investors to tread very cautiously. I would go so far as to say that until we see strong signs of a turnaround, rating the company a "Sell" is the right choice. This play has issues According to the management team at Clarus Corporation, the company operates as a designer, developer, producer, and distributor of outdoor equipment and lifestyle products. Its primary objective is to cater to outdoor enthusiasts. Although I am not personally all that much of an outdoors person, I used to be. I know plenty of people who are. And as somebody who spent a lot of my youth in those types of conditions, this kind of company creates a bit of nostalgia for me. Clarus Corporation To really understand the company, we should touch on exactly what it does. For starters, the business has its outdoor business, which consists of Black Diamond Equipment. This operates as a player in the climbing, skiing, a...